Information Provided By: 
Fly News Breaks for March 13, 2019
DRNA
Mar 13, 2019 | 07:30 EDT
SunTrust analyst Edward Nash raised his price target on Dicerna to $26 and kept his Buy rating , saying the company remains on track to initiate a pivotal trial of DCR-PHXC and the first quarter and expects to start dosing Chronic Hepatitis B Virus patients in Q2. The analyst contends that the proof-of-concept data from the Phase 1 study for the treatment of Chronic Hepatitis B Virus expected in Q4 of this year could lead to a "lucrative deal" and potentially mark a "key inflection point" for Dicerna shares.
News For DRNA From the Last 2 Days
There are no results for your query DRNA
